Health Care [ 6/12 ] | Pharmaceuticals [ 30/74 ]
NASDAQ | Common Stock
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.
The company's lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
The company was incorporated in 1995 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | 0.64 Decreased by -36.94% | - |
| Nov 7, 24 | 0.02 Increased by +287.00% | - |
| Aug 1, 24 | 0.03 Increased by +163.75% | - |
| May 7, 24 | 0.14 Increased by +1.54 K% | - |
| Mar 12, 24 | 1.02 Increased by +10.26 K% | - |
| Nov 7, 23 | -0.01 Decreased by -102.22% | - |
| Aug 8, 23 | -0.04 Decreased by -233.33% | - |
| May 4, 23 | -0.01 Increased by 0.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 81.47 M Decreased by -30.06% | 45.76 M Decreased by -36.67% | Increased by +56.17% Decreased by -9.45% |
| Sep 30, 24 | 10.01 M Increased by +8.39% | 1.34 M Increased by +441.91% | Increased by +13.43% Increased by +415.45% |
| Jun 30, 24 | 21.81 M Increased by +271.05% | 1.83 M Increased by +163.73% | Increased by +8.40% Increased by +117.18% |
| Mar 31, 24 | 25.43 M Increased by +205.54% | 10.28 M Increased by +1.22 K% | Increased by +40.41% Increased by +466.32% |
| Dec 31, 23 | 116.48 M Increased by +925.53% | 72.26 M Increased by +9.00 K% | Increased by +62.03% Increased by +967.92% |
| Sep 30, 23 | 9.24 M Decreased by -87.21% | -393.07 K Decreased by -101.19% | Decreased by -4.26% Decreased by -109.30% |
| Jun 30, 23 | 5.88 M Decreased by -64.73% | -2.88 M Decreased by -241.16% | Decreased by -48.92% Decreased by -500.24% |
| Mar 31, 23 | 8.32 M Decreased by -21.03% | -918.25 K Decreased by -154.33% | Decreased by -11.03% Decreased by -222.05% |